Cargando…
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
The current developments of the new biological drugs targeting interleukin 5 (IL-5) and IL-5 receptor allowed to expand the treatment options for severe hypereosinophilic asthma. Clinicians will then be able to choose between antibodies targeting either circulating IL-5 or its receptor expressed on...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241368/ https://www.ncbi.nlm.nih.gov/pubmed/30519580 http://dx.doi.org/10.1155/2018/5698212 |
_version_ | 1783371769278627840 |
---|---|
author | Bagnasco, Diego Caminati, Marco Ferrando, Matteo Aloè, Teresita Testino, Elisa Canonica, Giorgio Walter Passalacqua, Giovanni |
author_facet | Bagnasco, Diego Caminati, Marco Ferrando, Matteo Aloè, Teresita Testino, Elisa Canonica, Giorgio Walter Passalacqua, Giovanni |
author_sort | Bagnasco, Diego |
collection | PubMed |
description | The current developments of the new biological drugs targeting interleukin 5 (IL-5) and IL-5 receptor allowed to expand the treatment options for severe hypereosinophilic asthma. Clinicians will then be able to choose between antibodies targeting either circulating IL-5 or its receptor expressed on eosinophils and basophils. The available clinical trials consistently reported favorable results about the reduction of exacerbations rate, improvement in quality of life, and sparing of the systemic steroid use, with a favorable safety profile. Two of these new drugs are administered subcutaneously, mepolizumab every 4 weeks and benralizumab every 8 weeks, whereas reslizumab is given intravenously monthly on a weigh-based dose. In the future, the research actions will be involved in the identification of a single biomarker or multiple biomarkers for the optimal choice of biological agents to be properly prescribed. |
format | Online Article Text |
id | pubmed-6241368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-62413682018-12-05 Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma Bagnasco, Diego Caminati, Marco Ferrando, Matteo Aloè, Teresita Testino, Elisa Canonica, Giorgio Walter Passalacqua, Giovanni Biomed Res Int Review Article The current developments of the new biological drugs targeting interleukin 5 (IL-5) and IL-5 receptor allowed to expand the treatment options for severe hypereosinophilic asthma. Clinicians will then be able to choose between antibodies targeting either circulating IL-5 or its receptor expressed on eosinophils and basophils. The available clinical trials consistently reported favorable results about the reduction of exacerbations rate, improvement in quality of life, and sparing of the systemic steroid use, with a favorable safety profile. Two of these new drugs are administered subcutaneously, mepolizumab every 4 weeks and benralizumab every 8 weeks, whereas reslizumab is given intravenously monthly on a weigh-based dose. In the future, the research actions will be involved in the identification of a single biomarker or multiple biomarkers for the optimal choice of biological agents to be properly prescribed. Hindawi 2018-11-05 /pmc/articles/PMC6241368/ /pubmed/30519580 http://dx.doi.org/10.1155/2018/5698212 Text en Copyright © 2018 Diego Bagnasco et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Bagnasco, Diego Caminati, Marco Ferrando, Matteo Aloè, Teresita Testino, Elisa Canonica, Giorgio Walter Passalacqua, Giovanni Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma |
title | Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma |
title_full | Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma |
title_fullStr | Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma |
title_full_unstemmed | Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma |
title_short | Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma |
title_sort | anti-il-5 and il-5ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241368/ https://www.ncbi.nlm.nih.gov/pubmed/30519580 http://dx.doi.org/10.1155/2018/5698212 |
work_keys_str_mv | AT bagnascodiego antiil5andil5raefficacyandsafetyofnewtherapeuticstrategiesinsevereuncontrolledasthma AT caminatimarco antiil5andil5raefficacyandsafetyofnewtherapeuticstrategiesinsevereuncontrolledasthma AT ferrandomatteo antiil5andil5raefficacyandsafetyofnewtherapeuticstrategiesinsevereuncontrolledasthma AT aloeteresita antiil5andil5raefficacyandsafetyofnewtherapeuticstrategiesinsevereuncontrolledasthma AT testinoelisa antiil5andil5raefficacyandsafetyofnewtherapeuticstrategiesinsevereuncontrolledasthma AT canonicagiorgiowalter antiil5andil5raefficacyandsafetyofnewtherapeuticstrategiesinsevereuncontrolledasthma AT passalacquagiovanni antiil5andil5raefficacyandsafetyofnewtherapeuticstrategiesinsevereuncontrolledasthma |